Abstract

Background: Breast cancer represents the most frequently diagnosed form of cancer on a global scale and stands as the primary cause of cancer-related mortality among women. Metastasis of tumors constitutes a significant factor contributing to mortality in breast cancer cases. The urokinase-type plasminogen activator system, including uPA, uPAR, PAI-1 and PAI-2, is crucial for tumor progression and metastasis. Their combination is a validated prognostic marker for both node-negative and node-positive breast cancer, guiding treatment decisions for early breast cancer. This study aims to analyse uPA and PAI-1 levels in breast carcinoma patients and their correlation with disease stage, hormonal status, and potential use as prognostic indicators. Objective: To estimate the plasma levels of uPA and PAI-1 in patients with breast carcinoma and compare them to those in the control group. To correlate these markers (uPA and PAI-1) with other clinicopathological parameters. Methods: A cross-sectional analytical study was conducted on 30 biopsy-proven breast cancer patients. Blood samples were collected to analyse uPA and PAI-1 levels and coagulation profiles. The correlation between uPA and PAI-1 levels and other clinicopathological parameters was studied. Results: Our study observed a statistically significant association of uPA levels with increasing tumor size, higher tumor stage, lymphadenopathy and higher ki67 index (<0.05). On the contrary, the association of uPA levels with ER/PR and HER2/neu receptor status was insignificant. The association of high PAI-1 levels with higher clinical stage and ER-negative status of the tumor was statistically significant. (p<0.05). Both uPA and PAI-1 show co-elevation in most breast cancer patients. Conclusion: Plasma uPA/PAI-1 levels may provide important information in the risk stratification of patients with breast cancer and act as potential prognostic biomarkers.

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024.
2. International Agency for Research on Cancer. World Cancer Report [Internet]. 2020 [cited 4 April 2021]. Available from: https://www.iarc.who.int/cards_page/world-cancer-report/
3. Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics. 2012;9(5):311-320.
4. Durand MK, Bodker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, et al. Plasminogen activator inhibitor-1 and tumor growth, invasion, and metastasis. Thromb Haemost. 2004;91(03):438-449.
5. Kwaan HC, McMahon B. The role of the plasminogen-plasmin system in cancer. Cancer Treat Res. 2009; 148:43-66.
6. Zetter B. Angiogenesis and tumor metastasis. Annu Rev Med. 1998; 49:407-414
7. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer.2006;6(6):449-58.
8. Weigelt B, Peterse JL, Van’t Veer LJ. Breast cancer metastasis: markers and models.Nat Rev Cancer.2005; 5(8): 591.
9. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival infive continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–56. https://doi.org/10.1016/S1470-2045(08)70179-7
10. Arzanova E, Mayrovitz HN. The Epidemiology of Breast Cancer. Exon Publications. 2022 Aug 6:1-9.
11. Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer.2006;13: 1033-1067
12. Banys-Paluchowski M, Witzel I, Aktas B, Fasching PA, Hartkopf A, Janni W, et al. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Sci Rep. 2019 Feb 19;9(1):2318. https://doi.org/10.1038/s41598-018-37259-2
13. Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, Shi YJ, Fan Y, Guo DY. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. Journal of translational medicine. 2022 Mar 18;20(1):135.
14. Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, et al. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. Anticancer Res. 2014 Mar;34(3):1153-61.
15. Pusina S. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer. Med Arch. 2018 Nov;72(5):335-340.
16. Al-Nafakh Z, Al-Dujaili A, Rudha A. Assessment of plasminogen activator inhibitor-1(PAI-1) biomarker in women with breast cancer disease. AIP Conference Proceedings. 2020; 2290, 020043 https://doi.org/10.1063/5.0029591
17. Wrzeszcz K, Słomka A, Zarychta E, Rhone P, Ruszkowska-Ciastek B. Tissue Plasminogen Activator as a Possible Indicator of Breast Cancer Relapse: A Preliminary, Prospective Study. J of Clin Med. 2022 Apr 25;11(9):2398. https://doi.org/10.3390/jcm11092398.
18. Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast cancer research. 2014 Aug; 16:1-0.
19. Sobocan M, Ledinek Z, Crnobrnja B, Sikošek NČ, Dovnik NF, Kavalar R, Knez J, Takač I. The value of uPA and PAI-1 levels in triple negative breast cancer. European Journal of Cancer. 2020 Oct 1;138: S73-4.
20. Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N: Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. Breast Cancer Res Treat 2013, 138:839–850.